|
| Press Releases |
|
 |
|
| Saturday, August 31, 2013 |
|
|
NANOBIOTIX: Half Year Results for the Period Ended 30 June 2013 |
| NANOBIOTIX (the "Company") (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has published today its half year results for the six month period ended 30 June 2013 (HY1). more info >> |
|
| Thursday, July 4, 2013 |
|
|
Nanobiotix Announces EUR 2.8 Million Grant from bpifrance to Accelerate Development of NBTXR3 in a Third New Indication |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today it has secured c.EUR 9 million in funding from bpifrance (formerly OSEO) of which EUR 2.8 million is directly attributable to the Company. more info >> |
|
| Wednesday, June 26, 2013 |
|
|
Nanobiotix Announces the Selection of its Second NanoXray Product, NBTX-IV and a Collaboration with the National Cancer Institute for Development |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the selection of a new product for development, NBTX-IV. more info >> |
|
| Thursday, June 13, 2013 |
|
|
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO) announces today that its lead compound NBTXR3 has received authorization from the French Medicine Agency, ANSM, to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment center. more info >> |
|
| Monday, June 3, 2013 |
|
|
Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-based product, NBTXR3, in patients with Soft Tissue Sarcoma (STS). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises
Jun 9, 2025 19:30 HKT/SGT
|
|
|
SRKay Consulting Group Releases Research Report: 'From Legal Frameworks to Successful Operations'--A Strategic Playbook for India Market Entry
Jun 9, 2025 17:00 HKT/SGT
|
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
Jun 9, 2025 13:52: JST
|
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
Jun 9, 2025 12:52 HKT/SGT
|
|
|
雲頂新耀EVER001亮相ERA 2025 探索原發性膜性腎病治療新路徑
Jun 9, 2025 12:47 HKT/SGT
|
|
|
云顶新耀EVER001亮相ERA 2025 探索原发性膜性肾病治疗新路径
Jun 9, 2025 12:35 HKT/SGT
|
|
|
光大控股成功發行30億元人民幣熊貓中期票據
Jun 9, 2025 10:07 HKT/SGT
|
|
|
光大控股成功发行30亿元人民币熊猫中期票据
Jun 9, 2025 10:00 HKT/SGT
|
|
|
冠君产业信托呈献“Lupus Reimagined”艺术展 以艺术连结社区 共创多元共融未来
Jun 6, 2025 19:22 HKT/SGT
|
|
|
Champion REIT Presents 'Lupus Reimagined' Art Exhibition, Connecting Community Through Art
Jun 6, 2025 18:55 HKT/SGT
|
|
|
冠君產業信託呈獻「Lupus Reimagined」藝術展 以藝術連結社區 共創多元共融未來
Jun 6, 2025 18:23 HKT/SGT
|
|
|
稀有中高端冷冻海产上市公司大洋环球上月跑赢大市 最新财报有启示？
Jun 6, 2025 16:16 HKT/SGT
|
|
|
Tredu.com Launches Global Platform to Revolutionize Trading Education
Jun 6, 2025 16:00: JST
|
|
|
International Consortium Rolls Out Major EV Battery Swapping Initiative in Tokyo
Jun 6, 2025 16:42 JST
|
|
|
Tredu.com Launches Global Platform to Revolutionize Trading Education
Jun 6, 2025 15:40 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
